Oncimmune Holdings plc

LSE ONC.L

Oncimmune Holdings plc Total Non-Current Liabilities for the year ending August 31, 2023: USD 8.06 M

Oncimmune Holdings plc Total Non-Current Liabilities is USD 8.06 M for the year ending August 31, 2023, a 30.83% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Oncimmune Holdings plc Total Non-Current Liabilities for the year ending May 31, 2022 was USD 6.16 M, a -53.31% change year over year.
Oncimmune Holdings plc Total Non-Current Liabilities for the year ending May 31, 2021 was USD 13.19 M, a 51.70% change year over year.
Oncimmune Holdings plc Total Non-Current Liabilities for the year ending May 31, 2020 was USD 8.69 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

LSE: ONC.L

Oncimmune Holdings plc

CEO	Mr. Martin John Gouldstone
IPO Date	May 18, 2016
Location	United Kingdom
Headquarters	MediCity
Employees	38
Sector	Healthcare
Industries Biotechnology 3D Printing Big Data Clinical Trials Medical Instruments Pharmaceuticals Robotics Vaccines

Description

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Key trends

Past 5 years